During a Wednesday Senate budget hearing, Francis Collins, director of the National Institutes of Health (NIH) expressed positive remarks about the therapeutic potential of psychedelics such as psilocybin and MDMA.
“I think as we’ve learned more about how the brain works we began to realize that these are potential tools for research purposes and might be clinically beneficial,” Collins said.
The NIH is the country’s main health agency responsible for public health research. As its director, Collins stands as the highest ranking health officer in the federal government.
Psychedelics: Collins said there has been a resurgence of interest in psychedelic drugs, which for a while “were sort of considered not an area that researchers legitimately ought to go after.”
He went on to explain that psilocybin has been tested …